AZUKA OFODIKE: Open Payments
NPI 1922422617 · SOMERSET, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$213 in 12 payments from 7 companies in 2025. Trend: 2023 $65 · 2024 $48 · 2025 $213
Food & beverage: $213
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $53 |
| Neurocrine BioSciences, Inc. | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Alkermes, Inc. | 1 | $18 |
Products named: VRAYLAR, INGREZZA, HETLIOZ, ABILIFY ASIMTUFII, INVEGA SUSTENNA, ARISTADA, REXULTI.
Industry payments across NJ — which companies pay providers there.
